标题
The role of the JAK/STAT signal pathway in rheumatoid arthritis
作者
关键词
-
出版物
Therapeutic Advances in Musculoskeletal Disease
Volume 10, Issue 5-6, Pages 117-127
出版商
SAGE Publications
发表日期
2018-05-19
DOI
10.1177/1759720x18776224
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Filgotinib for the treatment of rheumatoid arthritis
- (2017) Peter C. Taylor et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate
- (2017) Roy Fleischmann EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy of baricitinib in the treatment of rheumatoid arthritis
- (2017) Christophe Richez et al. EXPERT OPINION ON PHARMACOTHERAPY
- Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis
- (2017) Charles Malemud INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Checkpoint inhibitors in hematological malignancies
- (2017) Chi Young Ok et al. Journal of Hematology & Oncology
- A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model
- (2017) Misato Ito et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor
- (2017) Fiona Elwood et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Pathogenetic insights from the treatment of rheumatoid arthritis
- (2017) Iain B McInnes et al. LANCET
- Searching for Novel Janus Kinase-2 Inhibitors Using a Combination of Pharmacophore Modeling, 3D-QSAR Studies and Virtual Screening
- (2017) Eleni Vrontaki et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
- (2017) Toshifumi Doi et al. ONCOLOGY REPORTS
- Malignancy and Janus Kinase Inhibition
- (2017) Padmapriya Sivaraman et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
- (2017) A. J. Kivitz et al. Arthritis & Rheumatology
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
- (2017) Frédéric Vanhoutte et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- (2016) A Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
- (2016) R Westhovens et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis
- (2016) Shingo Nakayamada et al. BIODRUGS
- SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?
- (2016) R. Mahony et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects
- (2016) Tong Zhu et al. CLINICAL PHARMACOKINETICS
- Janus kinase inhibitors for rheumatoid arthritis
- (2016) Kunihiro Yamaoka CURRENT OPINION IN CHEMICAL BIOLOGY
- p43 induces IP-10 expression through the JAK-STAT signaling pathway in HMEC-1 cells
- (2016) Wei Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-15 Activates the Jak3/STAT3 Signaling Pathway to Mediate Glucose Uptake in Skeletal Muscle Cells
- (2016) James E. Krolopp et al. Frontiers in Physiology
- Progress toward JAK1-selective inhibitors
- (2015) Christel J Menet et al. Future Medicinal Chemistry
- Protein Inhibitor of Activated STAT3 Regulates Migration, Invasion, and Activation of Fibroblast-like Synoviocytes in Rheumatoid Arthritis
- (2015) Minxi Lao et al. JOURNAL OF IMMUNOLOGY
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Immunological Consequences of JAK Inhibition: Friend or Foe?
- (2015) Donal P. McLornan et al. Current Hematologic Malignancy Reports
- Editorial: Decernotinib: A Next-Generation Jakinib
- (2015) Massimo Gadina et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Tofacitinib
- (2014) Deepti Vyas et al. ANNALS OF PHARMACOTHERAPY
- Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
- (2014) S. C. Meyer et al. CLINICAL CANCER RESEARCH
- Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis
- (2014) Kirandeep Kaur et al. CLINICAL THERAPEUTICS
- Advances in kinase inhibition
- (2014) Massimo Gadina CURRENT OPINION IN RHEUMATOLOGY
- IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells
- (2014) Aparna R. Shenoy et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Selective JAK inhibitors in development for rheumatoid arthritis
- (2014) Peter Norman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Dual Role of the Jak1 FERM and Kinase Domains in Cytokine Receptor Binding and in Stimulation-Dependent Jak Activation
- (2014) S. Haan et al. JOURNAL OF IMMUNOLOGY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia
- (2014) J. Munoz et al. ONCOLOGIST
- Cardiovascular disease in autoimmune rheumatic diseases
- (2013) Ivana Hollan et al. AUTOIMMUNITY REVIEWS
- The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
- (2013) Paweł Kawalec et al. CLINICAL RHEUMATOLOGY
- Small molecular compounds in development for rheumatoid arthritis
- (2013) Ronald F. van Vollenhoven CURRENT OPINION IN RHEUMATOLOGY
- Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
- (2013) Enrico Derenzini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
- (2013) L. Van Rompaey et al. JOURNAL OF IMMUNOLOGY
- Janus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases
- (2013) Massimo Gadina JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
- (2012) Apostolos Kontzias et al. CURRENT OPINION IN PHARMACOLOGY
- TWEAK signals through JAK–STAT to induce tumor cell apoptosis
- (2012) Mark S. Chapman et al. CYTOKINE
- Tofacitinib for the treatment of rheumatoid arthritis
- (2012) Cristiano AF Zerbini et al. Expert Review of Clinical Immunology
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- Cell-cell Interactions in Rheumatoid Arthritis Synovium
- (2010) David A. Fox et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
- (2009) Charles Malemud et al. Current Signal Transduction Therapy
- ERK inhibitors as a potential new therapy for rheumatoid arthritis
- (2009) M. Ohori DRUG NEWS & PERSPECTIVES
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis
- (2009) Beatrix Bartok et al. IMMUNOLOGICAL REVIEWS
- NF-κB regulation: the nuclear response
- (2009) Arun K. Mankan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The Immunopathogenesis of Rheumatoid Arthritis
- (2008) John B. Imboden Annual Review of Pathology-Mechanisms of Disease
- Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
- (2008) Jian-kang Jiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT
- (2007) Kazue Tsuji-Takayama et al. EXPERIMENTAL HEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now